4:46 PM
 | 
Sep 21, 2017
 |  BC Extra  |  Politics & Policy

Express Scripts’ Miller backs new pricing models for CAR T, gene therapy

In a blog post, Express Scripts Holding Co. (NASDAQ:ESRX) CMO Steve Miller called for new drug pricing and payment models for one-time, potentially curative treatments.

Miller said that while therapies such as Kymriah tisagenlecleucel, the first chimeric antigen receptor T cell (CAR T) therapy approved by FDA, hold great promise to provide durable treatment responses and possible cures after only one treatment, "the healthcare system isn't set...

Read the full 326 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >